



FOR IMMEDIATE RELEASE

**Baxter Media Contact**

Lauren Russ, (224) 948-5353  
[media@baxter.com](mailto:media@baxter.com)

**NantHealth Media Contact**

Jen Hodson, (562) 397-3639  
[jen@nantworks.com](mailto:jen@nantworks.com)

**Baxter Investor Contact**

Clare Trachtman, (224) 948-3085

**BAXTER AND NANTHEALTH® ADVANCE DIGITAL HEALTH TECHNOLOGY  
FOR MEDICAL DEVICES IN THE HOSPITAL ICU**

- *NantHealth has validated successful DeviceConX™ integration with Baxter's Prismaflex system, used to treat critically-ill patients in the ICU*
- *Connectivity is being used in multiple U.S. hospitals*
- *Baxter and NantHealth are also working on Baxter's next generation medical devices and expect DeviceConX™ validation at launch*

**ORLANDO, FEBRUARY 11, 2019** – NantHealth (NASDAQ: NH), a leader in connected care solutions, and Baxter International Inc. (NYSE:BAX), a global medical products company, today announced that a NantHealth digital health solution is now available to connect Baxter's **Prismaflex** system to a hospital electronic medical record (EMR). **Prismaflex** is used in the intensive care unit (ICU) to treat patients with acute kidney injury (AKI) and certain blood and autoimmune conditions, which can be life-threatening. The companies are demonstrating the technology at the 2019 Healthcare Information and Management Systems Society (HIMSS) Interoperability Showcase™ this week.

ICU clinicians treat patients with the most serious and complex conditions. Care in the ICU is also multi-disciplinary, with several specialists and nurses providing care for these complex cases. Despite these factors, technology and medical devices in the ICU remain largely disconnected and fragmented. These dynamics mean digital health solutions have the potential to positively impact patient care and hospital efficiency.

NantHealth has built a device driver allowing integration of its DeviceConX platform with the **Prismaflex** system. NantHealth's DeviceConX works with various electronic medical record (EMR)

systems and enables straightforward integration of information from the device to the EMR. This means ICU nurses can spend less time manually documenting treatment data, while reducing the risk of transcription errors. NantHealth and Baxter are also working to validate drivers for Baxter's next generation medical devices designed for the ICU.

"The ICU requires coordinated care among specialists and nurses, further complicated by the need to manage data streams from numerous medical devices," said Brian Tufts, Baxter's lead for Acute Therapies in the U.S. "When customers use technology to streamline connectivity of **Prismaflex** to their IT systems, busy nurses are no longer tasked with manually charting treatment data. We are excited about this development as we work to create digital health solutions to help our customers turn data into meaningful insights to improve patient care."

"Connected care solutions like those created by NantHealth provide important information for care team members to make more informed decisions about their patients," said Wesley Madden, BSN, RN, vice president of Connected Care for NantHealth. "We're proud to work with innovative companies like Baxter, who understand the importance of giving clinicians the very best tools and data to deliver the highest quality care possible."

NantHealth will be showcasing Baxter's recently integrated **Prismaflex** device in the HIMSS Interoperability Showcase in Hall F - Booth #9100, which brings together multiple vendors with kidney and dialysis treatment solutions.

**Prismaflex** is Rx Only: For safe and proper use of the devices mentioned herein, refer to the complete instructions in the Operator's Manual. The **Prismaflex** system is intended for continuous renal replacement therapies (CVVHDF, CVVHD, CVVH, SCUF) and therapeutic plasma exchange (TPE). The **Prismaflex** system should be restricted to patients with a body weight greater than 20 kg (44 lb).

### **About Acute Kidney Injury**

Acute kidney injury (AKI) is a sudden decrease in kidney function over a period of hours to days, often the result of illness, trauma or infection. The sudden loss of kidney function leads to the accumulation of toxins and fluid in the blood that, if left untreated, may lead to death. The most severe stage of AKI requires renal replacement therapy to replace the function of healthy kidneys. AKI is an increasingly common complication of acute illnesses in intensive care units and hospitals.<sup>1,2,3</sup>

### **About NantHealth**

NantHealth provides innovative solutions across the continuum of care for patients, physicians, payers and biopharmaceutical organizations. Connected Care, NantHealth's Medical Device Interoperability (MDI) solution, provides hundreds of healthcare facilities across the globe with vendor-neutral device connectivity. Our combined hardware-software offering delivers high

resolution, low-latency medical device data to a broad range of clinical systems, including EMRs and research databases. For more information, please visit <https://www.nanthhealth.com/>.

### **About Baxter**

Every day, millions of patients and caregivers rely on Baxter's leading portfolio of critical care, nutrition, renal, hospital and surgical products. For more than 85 years, we've been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers that make it happen. With products, technologies and therapies available in more than 100 countries, Baxter's employees worldwide are now building upon the company's rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit [baxter.com](http://baxter.com) and follow us on [Twitter](#), [LinkedIn](#) and [Facebook](#).

*This release includes forward-looking statements concerning the EMR technology and **Prismaflex** system referred to in this release, including anticipated benefits associated with their use and anticipated production certifications, and a potential partnership between Baxter and NantHealth. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; product quality, manufacturing or supply issues; patient safety issues; changes in law and regulations; breaches or failures of the company's information technology systems or products, including by cyberattack, unauthorized access or theft; and other risks identified in Baxter's most recent filing on Form 10-K and other SEC filings, all of which are available on Baxter's website. Baxter does not undertake to update its forward-looking statements.*

Baxter and **Prismaflex** are registered trademarks of Baxter International Inc.

###

---

<sup>1</sup>Siew ED, Davenport A: The growth of acute kidney injury: a rising tide or just closer attention to detail? *Kidney Int* 2015;87:46-61.

<sup>2</sup>O'Connor ME, Kirwan CJ, Pearse RM, Prowle JR: Incidence and associations of acute kidney injury after major abdominal surgery. *Intensive Care Med* 2016;42:521-530.

<sup>3</sup>Susantitaphong P, Cruz DN, Cerda J, Abulfaraj M, Alqahtani F, Koulouridis I, Jaber BL: World incidence of AKI: a meta-analysis. *Clin J Am Soc Nephrol* 2013;8:1482-1493.